Deucravacitinib

Deucravacitinib

  • Insufficient data are available for pregnancy category.

  • Sotyktu

  • Oral

  • TYK2

FDA

  • Moderate-to-Severe Plaque Psoriasis at dose of 6 mg orally daily

Infections 

  • Upper respiratory tract infections 

Cutaneous

  • Varicella zoster reactivation, HSV, acne, folliculitis, mouth ulcers

Laboratory changes

  • Increased creatinine phosphokinase
  • Hyperlipidemia/ hypertriglyceridemia

  • Metabolized by CYP1A2 to form major metabolite, also metabolized by other CYPs

Baseline

  • Complete blood count with differential
  • Electrolytes
  • Liver function tests
  • Lipid profile
  • Hepatitis B & C
  • Tuberculosis evaluation
  • Pregnancy test 

Vaccinations 

  • Age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination
  • Avoid use of live vaccines
  • Response to live or non-live vaccines not evaluated

Notes

  • Deucravacitinib demonstrated superiority versus placebo and apremilast across multiple efficacy endpoints in patients with moderate to severe plaque psoriasis, and was generally well tolerated